Is Arvinas, Inc. (NASDAQ:ARVN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arvinas, Inc. at current levels.
Post-vepdegestrant washout leaves Arvinas trading below cash with a real pipeline the market has written off entirely.
Where ARVN is headed
By late 2027, Arvinas looks nothing like the company the market is currently pricing. Vepdegestrant, the partnered breast cancer degrader that was supposed to be the crown jewel, has been reset in investors' minds after the VERITAC-2 readout disappointment cycle. What remains is a $582M market cap sitting on roughly $950M in cash and a Pfizer partnership that still carries meaningful economics on any second-generation ER degrader combinations. The stock trades at a price-to-book of 1.05. That is the market saying the pipeline is worth zero and the cash burns to nothing. Both statements cannot be true simultaneously.
Read the full Compass Direction on ARVN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $9.03).
See the full ARVN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Arvinas, Inc. (NASDAQ:ARVN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arvinas, Inc. at current levels. Post-vepdegestrant washout leaves Arvinas trading below cash with a real pipeline the market has written off entirely.
What is ARVN's Compass Score?
Arvinas, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ARVN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ARVN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.